NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

VolverVolver

Resultados 82 resultados LastUpdate Última actualización 05/08/2020 [14:21:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 4 nextPage   por página


ICARIIN DERIVATIVES FOR USE IN TREATING MYELODYSPLASIA SYNDROME

NºPublicación: EP3689420A1 05/08/2020

Solicitante:

H LEE MOFFITT CANCER CENTER & RES INSTITUTE INC [US]

AU_2019204363_A1

Resumen de: EP3689420A1

Disclosed are compounds of Formula II, III-A, V-A or VI-A, as defined herein, for use in treating myelodysplastic syndrome.

traducir

CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN

NºPublicación: EP3689383A1 05/08/2020

Solicitante:

US HEALTH [US]

JP_2020078322_A

Resumen de: EP3689383A1

The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.

traducir

NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA

NºPublicación: EP3687537A1 05/08/2020

Solicitante:

DANA FARBER CANCER INST INC [US]

CA_3072353_A1

Resumen de: WO2019067503A1

The present disclosure relates to inhibitors of USP7 useful in the treatment of and other USP7 mediated diseases, having the Formula: wherein R1, R2, R3, R4, R5, R 6, and n are described herein.

traducir

METHOD FOR DIAGNOSING LYMPHOMA VIA BACTERIAL METAGENOMIC ANALYSIS

NºPublicación: EP3690065A1 05/08/2020

Solicitante:

MD HEALTHCARE INC [KR]

KR_20190043447_A

Resumen de: EP3690065A1

The present invention relates to a method of diagnosing lymphoma by bacterial metagenomic analysis, and more particularly, to a method of diagnosing lymphoma by analyzing an increase or decrease in contents of specific bacterial extracellular vesicles by performing bacterial metagenomic analysis using normal individual and subject-derived samples. The extracellular vesicles secreted from bacteria present in the environment are absorbed into the body to have a direct influence on the development of cancer cells, and since it is difficult to diagnose lymphoma early before symptoms are shown, effective treatment is difficult. Therefore, by previously predicting the risk of the onset of lymphoma through metagenomic analysis of bacterial extracellular vesicles using a human-derived sample according to the present invention, a lymphoma risk group may be diagnosed and predicted early to delay the time of onset or prevent the onset of lymphoma with proper cure, and after onset, early diagnosis may be performed, thereby reducing the incidence of lymphoma and increasing a therapeutic effect.

traducir

METHOD OF USING ANTI-CD79B IMMUNOCONJUGATES

NºPublicación: EP3689910A2 05/08/2020

Solicitante:

HOFFMANN LA ROCHE [CH]

US_2019201382_A1

Resumen de: EP3689910A2

Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.

traducir

NON-HUMAN ANIMAL MODELS OF SÉZARY SYNDROME

NºPublicación: WO2020152331A1 30/07/2020

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV DE PARIS [FR]
ASSIST PUBLIQUE HOPITAUX PARIS APHP [FR]

Resumen de: WO2020152331A1

Sézary syndrome is a rare, aggressive, and leukemic form of cutaneous T-cell lymphoma (CTCL) characterized by erythroderma associated with generalized peripheral lymphadenopathy and circulating clonal malignant T cells called Sézary cells. Current animal models of Sézary syndrome are not satisfactory since no cutaneous symptoms or occurrence of metastases could be observed. Now the inventors developed a new non-human animal model that repeat the major cutaneous symptoms of the human disease. This model could be suitable for screening new drugs and biomarkers of the disease.

traducir

BISPECIFIC ANTI-CD28 X ANTI-CD22 ANTIBODIES AND USES THEREOF

NºPublicación: US2020239576A1 30/07/2020

Solicitante:

REGENERON PHARMA [US]

WO_2020132066_A1

Resumen de: US2020239576A1

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.

traducir

TRUNCATED GUINEA PIG L-ASPARAGINASE VARIANTS AND METHODS OF USE

NºPublicación: US2020239867A1 30/07/2020

Solicitante:

UNIV ILLINOIS [US]

CN_111050784_A

Resumen de: US2020239867A1

Variant guinea pig L-asparaginases which are truncated and humanized are described as are fusion proteins containing the L-asparaginase and use of the L-asparaginases in the treatment of cancers such as acute lymphoblastic leukemia and acute myeloid leukemia.

traducir

METHODS OF TREATING PRURIGO NODULARIS USING ANTI-IL-31RA ANTIBODY COMPOSITIONS

NºPublicación: US2020239581A1 30/07/2020

Solicitante:

ZYMOGENETICS INC [US]

WO_2006088855_A1

Resumen de: US2020239581A1

The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.

traducir

METHODS OF TREATING MULTIPLE MYELOMA

NºPublicación: US2020239589A1 30/07/2020

Solicitante:

SANOFI SA [FR]

Resumen de: US2020239589A1

The present disclosure provides methods for treating multiple myeloma (such as refractory multiple myeloma or relapsed and refractory multiple myeloma) in an individual who received at least two prior therapies for multiple myeloma. The methods comprise administering to the individual an anti-CD38 antibody, pomalidomide, and dexamethasone. Also provided are methods of improving renal impairment in an individual having multiple myeloma.

traducir

Anti-metalloprotease antibody for diagnosis and treatment of cancers

NºPublicación: AU2020205221A1 30/07/2020

Solicitante:

LUDWIG INST FOR CANCER RES LTD [US]
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
UNIV MONASH [AU]

US_2017008976_A1

Resumen de: AU2020205221A1

Abstract: Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumour cells That also express the putative tumour stem cell marker CD 133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight AD AMI 0 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.

traducir

Activin-ActRIIa antagonists and uses for promoting bone growth in cancer patients

NºPublicación: AU2020204583A1 30/07/2020

Solicitante:

ACCELERON PHARMA INC [US]

AU_2018204248_A1

Resumen de: AU2020204583A1

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.

traducir

PROTEOLYSIS TARGETING CHIMERIC MOLECULE, PREPARATION METHOD, AND APPLICATION

NºPublicación: WO2020151229A1 30/07/2020

Solicitante:

UNIV CHINA PHARMA [CN]

CN_109761970_A

Resumen de: WO2020151229A1

Disclosed are a proteolysis targeting chimeric molecule, a preparation method, and an application. The provided proteolysis targeting chimeric molecule can inhibit the expression of BCR-ABL and/or CRBN protein in BCR-ABL and/or CRBN positive leukemia K562 cells to varying degrees, and thus can be used for preparing a drug for treating BCR-ABL and/or CRBN positive leukemia, wherein the proteolysis targeting chimeric molecule when n = 3 has excellent photoisomerization activity, and can be used for prepare a reagent or drug for degrading BCR-ABL and/or CRBN protein by light regulation. Also provided is a method for synthesizing this series of proteolysis targeting chimeric molecules.

traducir

IL6 GENE SINGLE NUCLEOTIDE POLYMORPHISM MARKER FOR PREDICTING RISK OF DEVELOPING DRUG-INDUCED LEUKOPENIA AND METHOD FOR PREDICTING RISK OF LEUKOPENIA USING SAME

NºPublicación: WO2020153617A1 30/07/2020

Solicitante:

SEOUL NAT UNIV R&DB FOUNDATION [KR]
SEOUL NAT UNIV HOSPITAL [KR]

Resumen de: WO2020153617A1

The present invention relates to a composition for predicting the risk of developing leukopenia comprising a single nucleotide polymorphism marker in an IL6 gene and a method for predicting the risk of developing leukopenia using same. As the single nucleotide polymorphism marker in an IL6 gene according to the present invention has a high correlation with the risk of developing leukopenia induced by drugs, in particular thiopurine-based drugs, patients with high susceptibility to leukopenia occurring during thiopurine-based drug treatment from leukemia, Crohn's disease, ulcerative colitis, or organ transplantation etc. can be effectively predicted or diagnosed by using the single nucleotide polymorphism marker at an early stage, and by administering a drug suitable for the patient through such prediction and diagnosis, it is possible to efficiently perform patient-specific treatment that can achieve an optimal treatment effect. Furthermore, the single nucleotide polymorphism marker according to the present invention can be utilized in drug development studies for the treatment of drug-induced leukopenia.

traducir

INHIBITORS OF PROTEIN KINASES

NºPublicación: US2020239458A1 30/07/2020

Solicitante:

PORTOLA PHARM INC [US]

US_2018186783_A1

Resumen de: US2020239458A1

The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

traducir

METHODS FOR THE DETECTION AND TREATMENT OF LEUKEMIAS THAT ARE RESPONSIVE TO DOT1L INHIBITION

NºPublicación: US2020239963A1 30/07/2020

Solicitante:

MEMORIAL SLOAN KETTERING CANCER CENTER [US]

JP_2016533742_A

Resumen de: US2020239963A1

Disclosed are: (i) methods for identifying leukemia patients who (or leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication but who are nonetheless susceptible to treatment with DOT1L inhibitors; and (ii) methods for treating leukemia patients who (or inhibiting proliferation or inducing apoptosis of leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication with DOT1L inhibitors. The patients identified as susceptible and the patients (or cells) treated exhibit elevated expression of a IIOX cluster gene or of a HOX cluster-associated gene. Elevated expression of such genes can be measured, e.g., by quantitating the relevant RNA and comparing it to that of a healthy individual (or cell) or to a predetermined standard or it can be inferred by determining whether the patient or cell possesses a mutation that is associated with elevated HOX cluster gene or HOX cluster associated gene expression and thereby inferring that the relevant expression with be elevated.

traducir

METHODS AND COMPOSITIONS FOR USE OF TREX2 AS DIAGNOSTIC AND PROGNOSTIC MARKER FOR CANCER

NºPublicación: US2020239969A1 30/07/2020

Solicitante:

UNIV TEXAS [US]

WO_2019079255_PA

Resumen de: US2020239969A1

Provided here are methods of assessing prognosis for a patient who has been diagnosed with a type of cancer by measuring TREX2 mRNA expression in a biological sample from the patient, comparing the TREX2 mRNA expression in the biological sample to a reference value, and providing a prognosis based on alterations in the TREX2 mRNA expression and the type of cancer. Also provided here are methods of treating a patient with myelodysplastic syndrome by administering a therapeutically effective amount of a pharmaceutical composition that decreases TREX2 mRNA expression in the patient.

traducir

PROGNOSTIC MARKER FOR MYELOPROLIFERATIVE NEOPLASMS

NºPublicación: US2020239961A1 30/07/2020

Solicitante:

ROUSSY INST GUSTAVE [FR]

WO_2016207405_A1

Resumen de: US2020239961A1

The present inventors identified for the first time a germline genomic alteration that accounts for familial myeloproliferative neoplasms (MPN) and myeloid malignancies. More precisely, they identified a 700 kb germline duplication that predisposes patients to essential thrombocythemia (ET) with a high frequency of evolution to myelofibrosis (MF) secondary myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Two out of the 6 duplicated genes (namely ATG2B and GSKIP) have been shown to be overexpressed in hematopoietic progenitors, and this overexpression cooperates with classical mutations in JAK2, MPL and CALR to generate the MPN phenotype. The presence of the 700 kb germline duplication is thus of poor prognosis for a MPN patient. The present invention discloses a method for detecting a predisposition of developing a MPN, as well as a prognostic method for assessing the probability that an ET-suffering patient will develop a myelofibrosis a secondary MDS or an AML. It also discloses a treating method for delaying MPN worsening, said treating method involving the inhibition of the ATG2B and GSKIP duplicated genes.

traducir

TREATMENT OF T CELL LYMPHOMA

NºPublicación: WO2020152081A1 30/07/2020

Solicitante:

INNATE PHARMA [FR]

Resumen de: WO2020152081A1

The present invention relates to methods for the treatment of T cell lymphomas using compounds that specifically bind KIR3DL2 in combination with chemotherapeutic agents, notably gemcitabine and/or oxaliplatin. The treatments are particularly useful in the treatment of peripheral T cell lymphomas, for example PTCL-NOS.

traducir

PYRROLOBENZODIAZEPINE DERIVATIVES AS INHIBITORS OF NF-KAPPA B FOR THE TREATMENT OF PROLIFERATIVE DISEASES

NºPublicación: WO2020152462A1 30/07/2020

Solicitante:

KING S COLLEGE LONDON [GB]

Resumen de: WO2020152462A1

The invention relates to a compound of formula (I) or salts, solvates, stereoisomers, tautomers or combinations thereof, wherein the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; and R1 and R2 are either (i) R1 and R2 together form a double bond; (ii) R1 is H and R2 is OH; or (iii) R1 is H and R2 is OC1-6 alkyl; Y is N-RB, S or O; Y1 is N or C-R8; q is o or 1; Het is where the carbonyl of the Het group is attached to the Y- & Y1-containing heterocyclic ring; Y2 is N-RB, S or O; Y3 is N or C-R10; Y4 is N-RB, S or O; Y5 is N or C-R10; Rx is H, RB, (CH2)m-ORB, halo, (CH2)m-NHRB and CO2RB; and each RB is independently selected from H, C1-6 alkyl and C1-6 haloalkyl. The invention also describes pharmaceutical compositions, and kits comprising compounds of formula (I) and their use for treating proliferative diseases such as multiple myeloma or chronic lymphocytic leukaemia and as NF-κΒ inhibitors.

traducir

PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR

NºPublicación: US2020237673A1 30/07/2020

Solicitante:

PHARMACYCLICS LLC [US]

US_2019117579_A1

Resumen de: US2020237673A1

Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

traducir

COMBINATION THERAPY WITH A BET INHIBITOR AND A BCL-2 INHIBITOR

NºPublicación: US2020237779A1 30/07/2020

Solicitante:

HOFFMANN LA ROCHE [US]

CN_110891608_A

Resumen de: US2020237779A1

The present invention is directed to the combination therapy of multiple myeloma with a BET inhibitor and a Bcl-2 inhibitor.

traducir

CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS

NºPublicación: WO2020154531A1 30/07/2020

Solicitante:

MILLENNIUM PHARM INC [US]
MOLECULAR TEMPLATES INC [US]

US_2020231650_A1

Resumen de: WO2020154531A1

The instant invention provides binding proteins ("CD38-binding proteins") which each comprise (1) a CD38-binding region for cell-targeting and (2) a Shiga toxin A Subunit effector polypeptide ("Shiga toxin effector polypeptide"). The Shiga toxin effector polypeptide components of the CD38-binding proteins may comprise a combination of mutations relative to a wild-type Shiga toxin sequence providing (1) de-immunization and/or (2) a reduction in protease sensitivity; wherein each Shiga toxin effector polypeptide retains one or more Shiga toxin function, such as, e.g., stimulating cellular internalization, directing intracellular routing, catalytic activity, and/or potent cytotoxicity. The CD38- binding proteins may have one or multiple uses, e.g., the selective killing of a specific CD38- expressing cell-type; and more generally, for the diagnosis and treatment of cancers and disorders involving CD38-expressing cells, e.g., in CD38-positive hematopoietic cancers such as multiple myeloma.

traducir

MEANS AND METHODS FOR COUNTERACTING MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISORDERS

NºPublicación: US2020239593A1 30/07/2020

Solicitante:

AIMM THERAPEUTICS BV [NL]

ES_2729057_T3

Resumen de: US2020239593A1

The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.

traducir

METHOD AND KITS FOR IDENTIFYING OF CDK9 INHIBITORS FOR THE TREATMENT OF CANCER

Nº publicación: EP3686290A2 29/07/2020

Solicitante:

MEMORIAL SLOAN KETTERING CANCER CENTER [US]
ST JUDE CHILDRENS RES HOSPITAL [US]

US_2020054640_A1

Resumen de: EP3686290A2

A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of MYC indicates a sensitivity to a treatment by a CDK9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and lymphoma.

traducir

Página1 de 4 nextPage por página

punteroimgVolver